logo

Mallinckrodt Plc (MNK)



Trade MNK now with
  Date
  Headline
12/10/2019 6:46:21 AM Mallinckrodt Plans To Update Its Incentive Compensation Clawback Policy And Create Opioid Report
12/5/2019 6:47:18 AM Mallinckrodt Reports Final Results Of Exchange Transactions
11/26/2019 6:57:56 AM Mallinckrodt Announces Findings From Large Retrospective Study Of Acthar Gel In Treatment Of Respiratory Disease
11/5/2019 6:15:45 AM Mallinckrodt Q3 Loss Per Share From Cont. Opns Of $0.01 And Adj EPS $2.07
10/31/2019 4:36:32 PM Mallinckrodt Says UVADEX Approved In Australia
10/21/2019 10:18:02 AM Mallinckrodt To Present Results From Phase 3 CONFIRM Study Of Terlipressin In Patients With Hepatorenal Syndrome Type 1
10/1/2019 6:47:28 AM Mallinckrodt Says Positive Top-Line Findings From Observational Registry To Assess Treatment Response To Acthar Gel
9/23/2019 6:47:06 AM Mallinckrodt Announces Positive Top-line Results From Pivotal Phase 3 Clinical Trial Of StrataGraft® Regenerative Tissue
9/13/2019 6:49:16 AM Mallinckrodt:Acthar Gel May Be Cost-Effective Option Vs Other Late-Line, Adult Treatments For Multiple Sclerosis Relapse
9/10/2019 6:46:31 AM Mallinckrodt Agrees To Sell BioVectra Inc. To H.I.G. Capital For $250 Mln
8/15/2019 6:46:29 AM Mallinckrodt Reports Positive Top-Line Results From Pivotal Phase 3 CONFIRM Trial Of Terlipressin
8/12/2019 6:58:27 AM Mallinckrodt Confirms Enrollment Of First Patient In Phase 2a Study Of MNK-6106 In Hepatic Cirrhosis And Chronic HE
  
 
>